📰 Nuclear Enriched Transcript Sort News
Nuclear Enriched Transcript Sort News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nuclear Enriched Transcript Sort. Real-time updates on events, politics, business and more.
April 25, 2024
Boston US life science company Cerevance, which has facilities at Cambridge Science Park, has taken its Series B-1 round to a stunning $98 million after securing a $47m extension.
March 20, 2023
Positive CVN424 Phase 2 data for Parkinson’s disease to be presented Presentation of NETSseq platform’s ability to reveal novel targets to inform CNS drug...
February 13, 2023
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
August 11, 2022
Partnership will focus on the discovery of novel targets in Alzheimer’s disease - News - PharmaTimes
August 9, 2022
Merck is paying $25 million to kick off a research partnership with Cerevance, a startup that analyzes donor brain tissue to find novel targets for new neurological disorder drugs. While Cerevance’s lead program is a Parkinson’s disease drug, Merck is wants to see if the startup’s technology can help it discover and develop new Alzheimer’s disease drugs.